Cargando…
Notch Signaling Pathway and Endocrine Resistance in Breast Cancer
Nearly 70% of breast cancers express the estrogen receptor (ER) and are hormone-dependent for cell proliferation and survival. Anti-estrogen therapies with aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs) or selective estrogen receptor down regulators (SERDs) are the standa...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318302/ https://www.ncbi.nlm.nih.gov/pubmed/32636747 http://dx.doi.org/10.3389/fphar.2020.00924 |
_version_ | 1783550815763431424 |
---|---|
author | Bai, Jing-Wen Wei, Min Li, Ji-Wei Zhang, Guo-Jun |
author_facet | Bai, Jing-Wen Wei, Min Li, Ji-Wei Zhang, Guo-Jun |
author_sort | Bai, Jing-Wen |
collection | PubMed |
description | Nearly 70% of breast cancers express the estrogen receptor (ER) and are hormone-dependent for cell proliferation and survival. Anti-estrogen therapies with aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs) or selective estrogen receptor down regulators (SERDs) are the standard endocrine therapy approach for ER positive breast cancer patients. However, about 30% of patients receiving endocrine therapy will progress during the therapy or become endocrine resistance eventually. The intrinsic or acquired endocrine resistance has become a major obstacle for endocrine therapy. The mechanism of endocrine resistance is very complicated and recently emerging evidence indicates dysregulation of Notch signaling pathway contributes to endocrine resistance in breast cancer patients. The potential mechanisms include regulation of ER, promotion of cancer stem cell (CSC) phenotype and mesenchymal cell ratio, alteration of the local tumor microenvironment and cell cycle. This review will summarize the latest progress on the investigation of Notch signaling pathway in breast cancer endocrine resistance. |
format | Online Article Text |
id | pubmed-7318302 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73183022020-07-06 Notch Signaling Pathway and Endocrine Resistance in Breast Cancer Bai, Jing-Wen Wei, Min Li, Ji-Wei Zhang, Guo-Jun Front Pharmacol Pharmacology Nearly 70% of breast cancers express the estrogen receptor (ER) and are hormone-dependent for cell proliferation and survival. Anti-estrogen therapies with aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs) or selective estrogen receptor down regulators (SERDs) are the standard endocrine therapy approach for ER positive breast cancer patients. However, about 30% of patients receiving endocrine therapy will progress during the therapy or become endocrine resistance eventually. The intrinsic or acquired endocrine resistance has become a major obstacle for endocrine therapy. The mechanism of endocrine resistance is very complicated and recently emerging evidence indicates dysregulation of Notch signaling pathway contributes to endocrine resistance in breast cancer patients. The potential mechanisms include regulation of ER, promotion of cancer stem cell (CSC) phenotype and mesenchymal cell ratio, alteration of the local tumor microenvironment and cell cycle. This review will summarize the latest progress on the investigation of Notch signaling pathway in breast cancer endocrine resistance. Frontiers Media S.A. 2020-06-19 /pmc/articles/PMC7318302/ /pubmed/32636747 http://dx.doi.org/10.3389/fphar.2020.00924 Text en Copyright © 2020 Bai, Wei, Li and Zhang http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Bai, Jing-Wen Wei, Min Li, Ji-Wei Zhang, Guo-Jun Notch Signaling Pathway and Endocrine Resistance in Breast Cancer |
title | Notch Signaling Pathway and Endocrine Resistance in Breast Cancer |
title_full | Notch Signaling Pathway and Endocrine Resistance in Breast Cancer |
title_fullStr | Notch Signaling Pathway and Endocrine Resistance in Breast Cancer |
title_full_unstemmed | Notch Signaling Pathway and Endocrine Resistance in Breast Cancer |
title_short | Notch Signaling Pathway and Endocrine Resistance in Breast Cancer |
title_sort | notch signaling pathway and endocrine resistance in breast cancer |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318302/ https://www.ncbi.nlm.nih.gov/pubmed/32636747 http://dx.doi.org/10.3389/fphar.2020.00924 |
work_keys_str_mv | AT baijingwen notchsignalingpathwayandendocrineresistanceinbreastcancer AT weimin notchsignalingpathwayandendocrineresistanceinbreastcancer AT lijiwei notchsignalingpathwayandendocrineresistanceinbreastcancer AT zhangguojun notchsignalingpathwayandendocrineresistanceinbreastcancer |